Stellate Ganglion Morphine Infiltration on Myocardial Ischemia-Reperfusion Injury
China166 participantsStarted 2025-05-29
Plain-language summary
The goal of this clinical trial is to investigate whether morphine modulates the functions of the stellate ganglion to reduce myocardial ischemia/reperfusion injury in AMI patients. It will also assess the safety of injecting morphine around the stellate ganglion via ultrasound guidance. The main questions it aims to answer are:
1. Does morphine regulate stellate ganglion function to reduce myocardial ischemia/reperfusion injury in AMI patients?
2. What medical problems do participants experience when receiving injected morphine around the stellate ganglion? Researchers will compare morphine to a placebo saline (as a control group) to determine whether stellate ganglion infiltration with morphine effectively treats patients with AMI following primary PCI.
Participants will:
* Receive a single injection of morphine or saline around the stellate ganglion.
* Evaluate the percentage of infarct size 7 days after surgery, or at discharge if the duration is shorter than 7 days.
* Record their symptoms and any major adverse cardiovascular and cerebrovascular events within 30 days post-surgery.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Aged ≥18 years, Male or Female.
✓. Acute ST-segment elevation myocardial infarction (STEMI) patients planned for percutaneous coronary intervention (PCI). Acute STEMI is defined as: electrocardiogram shows ST-segment elevation ≥0.2 mV in two or more adjacent leads, or new left bundle branch block (LBBW).
✓. Within 24 hours of the onset of infarct-related chest pain.
✓. Obtaining informed consent from the patient and their family.
Exclusion criteria
✕. Patients with severe complications of myocardial infarction, such as uncontrollable acute left heart failure and pulmonary edema, severe cardiogenic shock after cardiopulmonary resuscitation, severe mechanical complications including ventricular septal defect, papillary muscle rupture, and rupture of the left ventricular free wall;
✕. Patients with old myocardial infarction, or cardiomyopathy, or malignant arrhythmias controlled by antiarrhythmic drugs;
✕. Patients with coagulation disorders due to systemic diseases and those who are currently using anticoagulants and are not suitable for injection;
What they're measuring
1
The percentage of myocardial infarct size
Timeframe: 7 days after primary PCI or at discharge
Trial details
NCT IDNCT06947135
SponsorThe Second Hospital of Anhui Medical University